InterCure (NASDAQ:INCR) vs. Immunic (NASDAQ:IMUX) Critical Contrast

Immunic (NASDAQ:IMUX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Immunic and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
InterCure	N/A	N/A	N/A

Insider and Institutional Ownership

51.8% of Immunic shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Immunic has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Immunic and InterCure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0	0	4	2	3.33
InterCure	0	0	0	0	0.00

Immunic presently has a consensus target price of $12.25, indicating a potential upside of 1,013.64%. Given Immunic’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunic is more favorable than InterCure.

Earnings & Valuation

This table compares Immunic and InterCure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61 million	($1.23)	-0.89
InterCure	$272.67 million	0.23	-$16.83 million	N/A	N/A

InterCure has higher revenue and earnings than Immunic.

Summary

Immunic beats InterCure on 7 of the 11 factors compared between the two stocks.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.